Merck and Ariad in billion-dollar cancer drug pact

Share this article:

Merck and Ariad Pharmaceuticals have agreed to the terms of a potential billion-dollar global collaboration deal to develop and market Ariad’s cancer treatment known as AP23573.
 
Merck will initially pay Cambridge, MA-based drug developer Ariad $75 million, up to $452 million in milestone payments and up to $200 million in sales bonuses, Merck said today in a statement. It is estimated that Merck will also spend at least $200 million on development costs for the drug and an additional $200 million to cover portions of Ariad's global development costs.

Ariad’s AP23573 is part of a new class of cancer treatments known as mTOR inhibitors, which are designed to block mTOR proteins and interfere with cancer cell growth.

AP23573 has been designated both as a fast-track product and an orphan drug by the FDA and as an orphan drug by the European Medicines Agency for the treatment of soft-tissue and bone sarcomas.

In June 2006, Ariad unveiled promising results from a Phase II study showing that AP23573 was effective in treating sarcoma patients.

A Phase III trial for AP23573 is set to begin this quarter. 

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...